Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07426757 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
A Phase 1 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT07426757 is a Phase 1 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 120 participants.
The verdict
NCT07426757, a Phase 1 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Interventions
- DRUG Midazolam
- DRUG PF-07994525
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-05-15 |
| Est. Completion | 2030-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07426757
The ClinicalTrials.gov registry entry for NCT07426757 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT07426757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07426757 about?
NCT07426757 is a clinical study titled "An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers". This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525...
What is the current status of trial NCT07426757?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2026-05-15. Estimated completion is 2030-07-10.
What interventions are being tested in trial NCT07426757?
The interventions under investigation include: Midazolam (DRUG), PF-07994525 (DRUG).
Who is sponsoring clinical trial NCT07426757?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.